Selpercatinib — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

3 Recruiting

5 Completed trials

5 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase IV

Phase I (FiH)

Phase III: 3 Phase II: 3 Phase I/II: 1 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Medullary thyroid cancer 2 Central nervous system neoplasm 1 Non-small cell lung cancer 1

Sponsors using this IMP

Eli Lilly & Co. 4 Loxo Oncology Inc. 2 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Oslo University Hospital HF 1 Region Hovedstaden 1

All trials

9 total

Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 Phase III 14 countries Eli Lilly & Co.
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu… Ended

2023-507703-63-00 Phase I/II 5 countries Loxo Oncology Inc.
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended

2023-506782-56-00 Phase III 9 countries Eli Lilly & Co.
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended

2023-506783-14-00 Phase III 7 countries Eli Lilly & Co.
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended

2023-507678-42-00 Phase IV 4 countries Eli Lilly & Co.
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors. Ended

2023-507702-13-00 Phase I (FiH) 5 countries Loxo Oncology Inc.

Showing 1–9 of 9 trials

← All drugs A–Z